Trius reports positive data from ESTABLISH 2 Phase 3 study of Tedizolid
Tedizolid met all primary and secondary efficacy outcomes designated by the FDA and EMA in the ESTABLISH 2 intravenous (IV) to oral transition study. Trius president and chief
Swedish Orphan Biovitrum (Sobi) has received a complete response letter from the US Food and Drug Administration (FDA) regarding its biologics licence application for nanoencapsulated sirolimus plus pegadricase (NASP), an investigational therapy intended for adults with uncontrolled gout.
New chemical entity acotiamide hydrochloride hydrate that inhibits peripheral acetylcholinesterase activities was invented by Zeria. Acofide works by suppressing the degradation of acetylcholine that is believed to play
Empagliflozin belongs to sodium glucose co-transporter-2 (SGLT2) inhibitor class of drugs, which blocks glucose re-absorption in the kidney and eliminates excess glucose through the urine. Boehringer Ingelheim metabolic-clinical